Bristol-Myers Squibb Co news

   Watch this stock
Showing stories 1 - 10 of about 151   

Articles published

BMY 58.19 -0.79 (-1.34%)
price chart
Dan Nathan Sees Unusual Options Activity In Bristol-Myers Squibb Co
A trader bought 7,500 contracts of the November 55 puts for $0.49, which sets the breakeven for this trade at $54.51. The trade followed a purchase of 150,000 stocks, so Nathan sees it as a protection for a long stock position.
Bristol-Myers Squibb a Top 25 Dividend Giant With 2.45% Yield (BMY)  Forbes
OliPass Announces a Worldwide Discovery Alliance with Bristol-Myers Squibb ...  Businessweek
Related articles »  
5 Things Bristol-Myers Squibb Co.'s Management Wants You to Know
Like most of its Big Pharma peers, Bristol-Myers Squibb (NYSE: BMY ) is undergoing major changes due to the patent cliff. Per its latest earnings report, for instance, the company saw third-quarter revenue drop by 4% to $3.92 billion, year over year ...
Bristol-Myers Squibb and Lonza Expand Manufacturing Agreement
NEW YORK & BASEL, Switzerland--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and Lonza today announced a multi-year expansion of their existing biologics manufacturing agreement.
Bristol-Myers Squibb Up on Positive Opdivo Phase II Study - Analyst Blog
Bristol-Myers Squibb Company ( BMY ) gained 8.9% after the company announced encouraging data from the phase II CheckMate - 063 study on immuno-oncology drug Opdivo (nivolumab, a PD-1 immune checkpoint inhibitor).
Bristol-Myers Squibb CEO Sells $2650000 in Stock (BMY)
Shares of Bristol-Myers Squibb (NYSE:BMY) traded up 7.39% during mid-day trading on Thursday, hitting $58.16. 13,065,821 shares of the company's stock traded hands. Bristol-Myers Squibb has a 52-week low of $46.30 and a 52-week high of $57.49.
Can Bristol-Myers Squibb Co (NYSE:BMY) Get it Done?
In the past year, the share price of Bristol-Myers Squibb Co (NYSE:BMY) have risen less than 1 percent, well below both the DJIA and the DRG, the NYSE Arca Pharmaceutical Index, a market-capitalization index designed to represent a cross section of ...
Bristol-Myers Squibb Co's Third-Quarter Earnings Beat the Street  Motley Fool
Bristol-Myers Squibb Given Neutral Rating at Zacks (BMY)  Ticker Report
Related articles »  
Bristol-Myers' Opdivo Improves Survival Rates For Lung Cancer Patients
Bristol-Myers Squibb Co (BMY) stock gained 8.9% in yesterday's trading session on positive trial results that showed that the company's experimental cancer drug Opdivo improved survival rates for late-stage lung cancer patients.
Bristol-Myers Squibb (BMY) Stock Is Gaining on Positive Phase 2 Results
"We rate BRISTOL-MYERS SQUIBB CO (BMY) a BUY. This is driven by some important positives, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover.
Morgan Stanley Believes Bristol-Myers Squibb Co. Could Move Significantly ...
In a report published Thursday, Morgan Stanley analyst David Risinger reiterated an Overweight rating and $60.00 price target on Bristol-Myers Squibb Co. (NYSE: BMY). In the report, Morgan Stanley noted, �We think BMY stock could move up 10�15% to ...
Bristol-Myers Squibb Presents Data from Multiple New Studies at IDWeek 2014 ...  Business Wire (press release)
Market Update: Bristol-Myers Squibb Company (NYSE:BMY) - Bristol-Myers ...  Jutia Group
Related articles »  
Bristol-Myers Squibb Co (BMY) Issues FY14 Earnings Guidance
Bristol-Myers Squibb logo Bristol-Myers Squibb Co (NYSE:BMY) updated its FY14 earnings guidance on Friday. The company provided EPS guidance of $1.70-1.80 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.78, ...